C8..
CANCELLED SEC. 8 (6-YR)
07/08/2026
Voltar para busca
Dado oficial do USPTO
ARINGAGE
Essa marca aparece no histórico oficial do USPTO.
Mesmo quando o status está encerrado, o histórico ajuda a calibrar o risco, evitar repetição de erros e definir uma estratégia segura de naming.
CANCELLED SEC. 8 (6-YR)Tipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
CANCELLED SEC. 8 (6-YR)
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
07/08/2026
Classificação
Inactive
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
30/04/2018
Data de registro
28/01/2020
Data de expiração
-
Ação recomendada
Use este histórico como insumo para naming, mas confirme disponibilidade atual em todas as classes relevantes.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/08/2026
Última transação
07/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
710
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Gangnam-gu, Seoul, KR
Examinador
FATHY, DOMINIC
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CMG Pharmaceutical Co.,Ltd.
Representantes
Miriam D. Trudell Davis Graham & Stubbs LLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; biological preparations for medical purposes for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; drugs for medical purposes for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; pharmaceuticals for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; multivitamins preparations; pharmaceutical preparations for diagnosis for medical orveterinary purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; preparations of microorganisms for medical and veterinary use for the treatment of cardiovascular diseasecentral nervous system disease and disordersneurological disordersurologicalurogenital and urinary disordersgastrointestinal disordersmusculoskeletal disordersstrokecancerinflammation and inflammatory diseasesrespiratory and infectious diseaseauto-immune disease; antibiotics
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
28/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/11/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
14/11/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
28/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/11/2019
PUBO
PUBLISHED FOR OPPOSITION
12/11/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/09/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/09/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/09/2019
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
11/07/2019
GPRA
PRIORITY ACTION E-MAILED
11/07/2019
CPRA
PRIORITY ACTION WRITTEN
11/07/2019
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/07/2019
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
26/03/2019
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
12/03/2019
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
08/03/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/02/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/02/2019
ALIE
ASSIGNED TO LIE
13/02/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/02/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/08/2018
GNRT
NON-FINAL ACTION E-MAILED
21/08/2018
CNRT
NON-FINAL ACTION WRITTEN
21/08/2018
DOCK
ASSIGNED TO EXAMINER
21/08/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/05/2018
NWAP
NEW APPLICATION ENTERED
03/05/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ARINGAGE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.